Esperion Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Robert E. Hoffman, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
J Martin Carroll, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
Jay Shepard, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
Seth H. Z. Fischer, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
John Craig Thompson, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
John B. Harlow Jr., Chief Commercial Officer of Esperion Therapeutics, Inc., reported a transaction in 424,536 shares of common stock on July 13, 2026.
NASDAQ
Benjamin Looker, Chief Legal Officer of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
Sheldon L. Koenig, President and CEO and a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
NASDAQ
Benjamin Looker, Chief Legal Officer at Esperion Therapeutics, sold 11,824 shares of common stock on June 17, 2026, to cover tax obligations.
NASDAQ
Sheldon L. Koenig, President and CEO of Esperion Therapeutics, reported a transaction involving the sale of common stock.
NASDAQ
Esperion Therapeutics, Inc. Chief Financial Officer, Benjamin Halladay, reported a sale of 10,773 shares of common stock on June 17, 2026, to cover tax obligations.
NASDAQ
John Craig Thompson, a Director at Esperion Therapeutics, Inc., has acquired 79,873 shares of common stock.
NASDAQ
Director Jay Shepard of Esperion Therapeutics, Inc. reported a transaction involving common stock on May 28, 2026.
NASDAQ
Robert E. Hoffman, a Director at Esperion Therapeutics, Inc., has reported transactions involving common stock, including the acquisition of 79,873 shares.
NASDAQ
Esperion Therapeutics Director Seth Fischer reports a transaction involving 79,873 shares of common stock, acquired on May 28, 2026.
NASDAQ
Esperion Therapeutics, Inc. director J. Martin Carroll reported a transaction involving 79,873 shares of common stock.
NASDAQ
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, sold 5,708 shares of common stock to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics CEO Sheldon L. Koenig sold 25,578 shares of common stock to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 6,424 shares of common stock to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, was granted 300,840 shares of common stock and options to purchase 269,230 shares.
NASDAQ
Esperion Therapeutics' President and CEO, Sheldon L. Koenig, acquired a significant number of common shares and stock options, increasing his beneficial ownership.
NASDAQ
Esperion Therapeutics' CFO, Benjamin Halladay, was granted 247,430 shares of common stock and options for 221,270 shares, vesting over four years.
NASDAQ
Esperion Therapeutics' General Counsel, Benjamin Looker, reported a planned sale of 1,689 common shares to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' President and CEO, Sheldon L. Koenig, sold 48,244 shares of common stock to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 7,337 shares of common stock to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 6,517 shares of common stock at $3.667 per share to cover tax obligations on vested restricted stock units.
NASDAQ
Esperion Therapeutics' Chief Commercial Officer, John B. Harlow Jr., received an award of 424,536 common shares and 380,000 stock options.
NASDAQ
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 1,248 shares of common stock to cover tax obligations related to vested restricted stock units.
NASDAQ
Esperion Therapeutics' General Counsel, Benjamin Looker, sold 6,267 shares of common stock to cover tax obligations related to vested restricted stock units.